We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

WBC Count Could Predict Severity of COVID-19 Symptoms

By LabMedica International staff writers
Posted on 03 Feb 2025
Image: Leukocyte count represents an easily accessible, inexpensive clinical marker (Photo courtesy of 123RF)
Image: Leukocyte count represents an easily accessible, inexpensive clinical marker (Photo courtesy of 123RF)

The global health crisis caused by the SARS-CoV-2 virus continues to impact millions of people worldwide, with many experiencing persistent symptoms months after the initial diagnosis. Cognitive impairment and fatigue are among the most common lingering effects, with a staggering 70% of patients suffering from cognitive impairment. Older adults, particularly women, are disproportionately affected. Despite significant advances in understanding COVID-19 since its emergence in 2020, several aspects of its impact on the human body remain unclear. While COVID-19 is primarily a respiratory disease, research has revealed widespread effects on multiple organ systems. Previous studies have identified an exaggerated immune response to COVID-19 infection. Now, a new study has shed light on a potential indicator of the most likely patients to experience severe symptoms of COVID-19 infection: leukocyte (white blood cell) count.

This study drew on data from the Women's Health Initiative, a comprehensive research project funded by the National Institutes of Health (NIH, Bethesda, MD, USA). Researchers sought to investigate pre-existing risk factors that might make older adults, particularly postmenopausal women, more susceptible to prolonged and severe symptoms. They examined the relationship between leukocyte count, a readily available clinical marker of systemic inflammation, and COVID disease outcomes. Their findings, published in the journal Menopause, suggest that leukocyte count is a reliable predictor of COVID symptom severity in postmenopausal women. This research contributes to the growing evidence that low-grade inflammation is not only an outcome of severe COVID-19 symptoms but also a potential precursor to the acute infection. Further investigation is needed, but the initial findings hold promise, as leukocyte count represents a relatively inexpensive and easily accessible clinical marker.

“As the authors highlight, post-acute sequelae of severe acute respiratory coronavirus 2 infection significantly affects quality of life, often leading to severe disability,” said Dr. Monica Christmas, associate medical director for The Menopause Society. “This effect is particularly pronounced in women, who already experience higher rates of cognitive impairment after menopause. By understanding underlying factors, we can better address these challenges and work to mitigate the cascade of symptoms that follow.”

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Automated Urinalysis Solution
UN-9000

Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more